AN2 Therapeutics Company Insiders
| ANTX Stock | USD 1.39 0.05 3.73% |
AN2 Therapeutics employs about 41 people. The company is managed by 11 executives with a total tenure of roughly 96 years, averaging almost 8.0 years of service per executive, having 3.73 employees per reported executive. Break down of AN2 Therapeutics' management performance can provide insight into the company performance.
AN2 |
AN2 Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.4289) % which means that it has lost $0.4289 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6948) %, meaning that it created substantial loss on money invested by shareholders. AN2 Therapeutics' management efficiency ratios could be used to measure how well AN2 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.49 in 2024. Return On Capital Employed is likely to drop to -0.59 in 2024. At this time, AN2 Therapeutics' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 29.6 M in 2024, whereas Total Assets are likely to drop slightly above 69.6 M in 2024.Common Stock Shares Outstanding is likely to drop to about 21.8 M in 2024. Net Loss is likely to drop to about (40.4 M) in 2024
AN2 Therapeutics Workforce Comparison
AN2 Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 824. AN2 Therapeutics holds roughly 41.0 in number of employees claiming about 5% of equities under Health Care industry.
AN2 Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AN2 Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on AN2 Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, AN2 Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Aziz Kabeer a day ago Disposition of 83337 shares by Aziz Kabeer of AN2 Therapeutics at 16.28 subject to Rule 16b-3 | ||
Day Lucy over a month ago Acquisition by Day Lucy of 27500 shares of AN2 Therapeutics subject to Rule 16b-3 | ||
Krause Kevin Michael over three months ago Acquisition by Krause Kevin Michael of 62200 shares of AN2 Therapeutics at 14.29 subject to Rule 16b-3 | ||
Joseph Zakrzewski over six months ago Acquisition by Joseph Zakrzewski of 23742 shares of AN2 Therapeutics at 5.91 subject to Rule 16b-3 | ||
Aziz Kabeer over six months ago Disposition of tradable shares by Aziz Kabeer of AN2 Therapeutics at 16.0 subject to Rule 16b-3 | ||
Krause Kevin Michael over six months ago Acquisition by Krause Kevin Michael of 60000 shares of AN2 Therapeutics at 3.0 subject to Rule 16b-3 | ||
Joseph Zakrzewski over six months ago Sale by Joseph Zakrzewski of 100000 shares of AN2 Therapeutics | ||
Readnour Robin Shane over a year ago Conversion by Readnour Robin Shane of 285156 shares of AN2 Therapeutics |
AN2 Therapeutics Notable Stakeholders
An AN2 Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as AN2 Therapeutics often face trade-offs trying to please all of them. AN2 Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting AN2 Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Lucy CPA | Principal CFO | Profile | |
| MBA BS | Chief Officer | Profile | |
| Eric Easom | CEO, Cofounder | Profile | |
| Paul MD | Chief Officer | Profile | |
| Sanjay Chanda | Chief Officer | Profile | |
| Josh Eizen | Chief Sec | Profile | |
| Jennifer Huber | Senior Quality | Profile | |
| Michael Alley | CoFounder Biology | Profile | |
| Joshua JD | Chief Secretary | Profile | |
| MD FACP | CoFounder Advisor | Profile | |
| Joseph Zakrzewski | Cofounder Chairman | Profile |
About AN2 Therapeutics Management Performance
The success or failure of an entity such as AN2 Therapeutics often depends on how effective the management is. AN2 Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of AN2 management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the AN2 management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.47) | (0.49) | |
| Return On Capital Employed | (0.56) | (0.59) | |
| Return On Assets | (0.47) | (0.49) | |
| Return On Equity | (0.52) | (0.49) |
Please note, the imprecision that can be found in AN2 Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AN2 Therapeutics. Check AN2 Therapeutics' Beneish M Score to see the likelihood of AN2 Therapeutics' management manipulating its earnings.
AN2 Therapeutics Workforce Analysis
Traditionally, organizations such as AN2 Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare AN2 Therapeutics within its industry.AN2 Therapeutics Manpower Efficiency
Return on AN2 Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.6M | |
| Net Loss Per Executive | 5.9M | |
| Working Capital Per Employee | 2.4M | |
| Working Capital Per Executive | 8.8M |
Additional Tools for AN2 Stock Analysis
When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.